It’s really important to get CAR-T available across the globe, particularly in lower-income countries, because it has a curative chance. And in fact, the overall burden that’s placed on patients financially may be less if we can give them CAR-T earlier. And I think in order to do this, the manufacturers of CAR-Ts, Janssen and others, should definitely approach regulatory agencies, especially with strong data coming out from early clinical trials, showing durable responses...
It’s really important to get CAR-T available across the globe, particularly in lower-income countries, because it has a curative chance. And in fact, the overall burden that’s placed on patients financially may be less if we can give them CAR-T earlier. And I think in order to do this, the manufacturers of CAR-Ts, Janssen and others, should definitely approach regulatory agencies, especially with strong data coming out from early clinical trials, showing durable responses. And this, I’m sure will lead to greater acceptance and even financial reimbursement that will allow for equitable access.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.